4 completed, 2 recruiting, 1 active not recruiting, 1 terminated. 3 Phase 3, 2 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow Adenosquamous Carcinoma: new trials by email Literature Review of Adenosquamous Carcinoma trials Research Report on Adenosquamous Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multicenter Trial of ESK981 in Patients With Select Solid Tumors ESK981 - Pancreatic Adenocarcinoma, Adenosquamous Carcinoma | Phase 2 | Active not recruiting | University of Michigan Rogel Cancer Center | 17 | 2024-04-19 | 2026-05-14 |
| PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer Standard treatment: Control arm, Experimental arm - Cervical Carcinoma, Adenocarcinoma | Phase 3 | Recruiting | Institut Claudius Regaud | 510 | 2023-12-20 | 2026-10-13 |
| A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China Diagnostic Test: Sputum DNA methylation analysis, chest CT or pathological examination - Lung Cancer, Small Cell Lung Cancer | Completed | Creative Biosciences (Guangzhou) Co., Ltd. | 1564 | 2022-02-25 | 2025-03-21 | |
| Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide - Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 20 | 2017-10-11 | 2023-07-24 |
| T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer Aldesleukin, Fludarabine, Cyclophosphamide - Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 85 | 2014-10-23 | 2026-10-20 |
| Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix Extraperitoneal laparoscopic lymphadenectomy (EPLND), Chemoradiation - Cervical Squamous Cell Carcinoma, Adenosquamous Carcinoma | Phase 3 | Completed | M.D. Anderson Cancer Center | 28 | 2011-08-01 | 2021-02-03 |
| Impact of Positron Emission Tomography (PET) Imaging in Women With Locally Advanced Cervical Cancer (PET LACE Trial) CT Abdomen and Pelvis scan + whole body PET-CT scan, CT Abdomen and Pelvis scan - Cervical Cancer, Squamous Cell Carcinoma | Not applicable | Completed | Ontario Clinical Oncology Group (OCOG) | 171 | 2010-04-01 | 2020-01-29 |
| Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer hysterectomy - Stage IB2 Cervical Cancer, Stage II Cervical Cancer | Phase 3 | Terminated | UNICANCER | 61 | 2003-05-01 | 2011-06-01 |
Carcinoma, Adenosquamous (8) · Adenocarcinoma (7) · Carcinoma, Squamous Cell (5) · Uterine Cervical Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Lung Neoplasms (2) · Adenoma, Islet Cell (1) · Bronchitis (1) · Bronchitis, Chronic (1) · Carcinoma (1) · Carcinoma, Large Cell (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Neoplasm Metastasis (1) · Pneumonia (1) · Pulmonary Disease, Chronic Obstructive (1)
Neoplasms (8) · Neoplasms by Histologic Type (8) · Neoplasms by Site (8) · Neoplasms, Complex and Mixed (8) · Neoplasms, Glandular and Epithelial (8) · Carcinoma (7) · Neoplasms, Squamous Cell (5) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Genital Diseases (4) · Genital Diseases, Female (4) · Genital Neoplasms, Female (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Uterine Cervical Diseases (4)
Cyclophosphamide (2) · aldesleukin (2) · fludarabine (2) · 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one (1) · Chemoradiotherapy (1) · Hysterectomy (1) · Interleukin-2 (1) · Nivolumab (1) · fludarabine phosphate (1)
Creative Biosciences (Guangzhou) Co., Ltd. (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Institut Claudius Regaud (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Ontario Clinical Oncology Group (OCOG) (1) · UNICANCER (1) · University of Michigan Rogel Cancer Center (1)
United States (4) · France (2) · Belgium (1) · Canada (1) · China (1) · Czechia (1) · Italy (1) · Spain (1)
Anthony Fyles, MD (1) · Ben Creelan, M.D. (1) · Douglas Coyle, PhD (1) · Greg Pond, PhD (1) · James C Yang, M.D. (1) · Karen Gulenchyn, MD (1) · Laiyu Liu, PhD (1) · Laurie Elit, MD (1) · Lei Zheng, PhD (1) · Mark Levine, MD (1) · Michael M. Frumovitz, MD, MPH (1) · Mostafa Atri, MD (1) · Vaibhav Sahai (1)